We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Stem Cell Therapeutics Announces the Issuance of United States Patent Number 7,964,563 for Prolactin

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Stem Cell Therapeutics Announces the Issuance of United States Patent Number 7,964,563 for Prolactin"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Stem Cell Therapeutics Corp. has announced that a patent by the U.S. Patent and Trademark Office -U.S. Patent 7,964,563 was granted.

The patent is entitled, "Oligodendrocyte Precursor Cell Proliferation Regulated By Prolactin." Claims granted in this Stem Cell Therapeutics Corp/ Patent focus protecting the therapeutic use of Prolactin for Multiple Sclerosis.

Dr. Allen Davidoff, SCT's Chief Scientific Officer, commented as follows: "We are very pleased by the granting of this patent, as it represents a cornerstone achievement in SCT's strategy to protect the use of prolactin for treating central nervous system disorders that involve white matter, and specifically for the treatment of Multiple Sclerosis.

This patent builds upon the strong basic scientific evidence that prolactin possesses the ability to stimulate endogenous stem cells to increase oligodendrocytes precursor cells in animals with central nervous system injuries and importantly increase the amount of myelin in white matter lesions. The anticipated MS clinical trial for the prolactin development program will substantially advance SCT's understanding how this important, novel neuro-regenerative therapy affects recovery in MS patients."